CoChat

Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future

Open access
Cummings, Jeffrey, Ritter, Aaron, Zhong, Kate · 2018 · Journal of Alzheimer's Disease

The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) has no currently approved disease-modifying therapies (DMTs), and treatments to prevent, delay the onset, or slow the progression are urgently needed. A delay of 5 years if available by 2025 would decrease the total number of patients with AD by 50% in 2050. To meet the definition of DMT, an agent must produce an enduring change in the course of AD; clinical trials of DMTs have the goal of demonstrating this effect. AD drug discovery entails target identification followed by high throughput screening and lead optimization of drug-like compounds. Once an optimized agent is available and has been assessed for efficacy and toxicity in animals, it progresses through Phase I testing with healthy volunteers, Phase II learning trials to establish proof-of-mechanism and dose, and Phase III confirmatory trials to demonstrate efficacy and safety in larger populations. Phase III is followed by Food and Drug Administration review and, if appropriate, market access. Trial populations include cognitively normal at-risk participants in prevention trials, mildly impaired participants with biomarker evidence of AD in prodromal AD trials, and subjects with cognitive and functional impairment in AD dementia trials. Biomarkers are critical in trials of DMTs, assisting in participant characterization and diagnosis, target engagement and proof-of-pharmacology, demonstration of disease-modification, and monitoring side effects. Clinical trial designs include randomized, parallel group; delayed start; staggered withdrawal; and adaptive. Lessons learned from completed trials inform future trials and increase the likelihood of success.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-179901

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.1 Overview of the drug development process.
Fig.1 Overview of the drug development process.CC BY-NC · PubMed Central
Fig.2 Origin of compounds that are assayed through high throughput screening to produce “hits” that are then subject to medicinal chemistry refinement to produce leads and optimized leads.
Fig.2 Origin of compounds that are assayed through high throughput screening to produce “hits” that are then subject to medicinal chemistry refinement to produce leads and optimized leads.CC BY-NC · PubMed Central
Fig.3 Roles of biomarkers in Phase II of drug development (BACE inhibition is included as an example of one type of target engagement biomarker; each drug mechanism will have a corresponding target engagement/proof of pharmacology biomarker), CSF, cerebrospinal fluid; AD, Alzheimer’s disease; fMRI, functional magnetic resonance imaging; QEEG, quantitative electroencephalography; FDG PET, fluorodeoxyglucose positron emission tomography; NF-light, neurofilament light chain protein; ARIA, amyloid-related imaging abnormalities.
Fig.3 Roles of biomarkers in Phase II of drug development (BACE inhibition is included as an example of one type of target engagement biomarker; each drug mechanism will have a corresponding target engagement/proof of pharmacology biomarker), CSF, cerebrospinal fluid; AD, Alzheimer’s disease; fMRI, functional magnetic resonance imaging; QEEG, quantitative electroencephalography; FDG PET, fluorodeoxyglucose positron emission tomography; NF-light, neurofilament light chain protein; ARIA, amyloid-related imaging abnormalities.CC BY-NC · PubMed Central
Fig.4 Negative (normal) and positive (abnormal; consistent with AD) amyloid PET images.
Fig.4 Negative (normal) and positive (abnormal; consistent with AD) amyloid PET images.CC BY-NC · PubMed Central
Fig.5 Critical data to be accrued in each stage of drug discovery and development (ADMET – absorption, distribution, metabolism, excretion, toxicity; BBB – blood brain barrier; MTD – maximum tolerated dose).
Fig.5 Critical data to be accrued in each stage of drug discovery and development (ADMET – absorption, distribution, metabolism, excretion, toxicity; BBB – blood brain barrier; MTD – maximum tolerated dose).CC BY-NC · PubMed Central
Fig.6 Phases of Alzheimer’s disease (AD) as defined by cognitive, functional, and biomarker observations. Trial goals for each phase are noted.
Fig.6 Phases of Alzheimer’s disease (AD) as defined by cognitive, functional, and biomarker observations. Trial goals for each phase are noted.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 114 references

Research works printed but not linked: 1

  1. Cummings, 2017, Defining disease modification for Alzheimer’s disease clinical trials, J Prev Alzheimers Dis, 4, 109

Cited by

Metadata

Authors
Cummings, J., Ritter, A., & Zhong, K.
Affiliations
  • Cleveland Clinic (US)
  • Global Alzheimer's Platform Foundation (US)
Corresponding author
Cummings, Jeffrey
Venue
Journal of Alzheimer's Disease
Published
2018-06-12
Volume
64
Issue
s1
Pages
S3-S22
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2789238556
Cited by
176
References
114
Citations by year
2026: 11 · 2025: 23 · 2024: 14 · 2023: 19 · 2022: 25 · 2021: 38 · 2020: 18 · 2019: 22 · 2018: 5
FWCI
2.72
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of General Medical Sciences (P20GM109025)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, disease-modifying therapy
MeSH terms
Alzheimer Disease, Animals, Clinical Trials as Topic, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.